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Standards are a powerful force in the protection of public health and safety, the development and 
commercialization of new technologies, and facilitation of national and international commerce. In the field of 
regenerative medicine, the need for standards has emerged as a common gap from various workshops, 
meetings, and discussion forums. 
 
Here we provide an update on multiple collaborative efforts between the U.S. Food & Drug Administration (FDA) 
and the National Institute of Standards and Technology (NIST), to support standards development for 
regenerative medicine R&D, manufacturing, and translation. Collaborative efforts include coordinated 
workshops, leadership and participation in standards development efforts within relevant SDOs, and joint 
research projects. These collaborations leverage NIST expertise in measurement sciences to address specific 
analytical scientific challenges as well as leveraging FDA regulatory expertise in regenerative medicine products 
to ensure that the science and standards developed address significant regulatory challenges that recur across 
the field.   
 
This talk will focus on joint FDA-NIST efforts to develop standards within ISO/TC 276: Biotechnology, and 
several collaborative projects on cell counting and cell viability to support the development of standards.  Cell 
viability is an important quality attribute often used as a manufacturing in-process control or a release criterion 
for cell therapy products.  Assurance for cell viability measurements has been particularly difficult due to 
ambiguities in the definition of viable cells as well as measurement challenges associated with quantifying cell 
health. The joint FDA-NIST project in cell viability aims to provide strategies for establishing validation protocols 
for cell viability measurements. 
 
 
